Applied dna's biotherapeutics subsidiary publishes manuscript demonstrating that a lineardna™ vaccine candidate was protective in virus challenge trial in ferrets

Stony brook, n.y.--(business wire)---- $apdn #lineardna--applied dna sciences, inc. (nasdaq: apdn) (‘applied dna' or the “company”), a leader in polymerase chain reaction (pcr”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a lineardna™-based vaccine candidate (the “vaccine candidate”) reduced infectious virus shedding and was protective against sars-cov-2 in a challenge trial in ferrets. the p
APDN Ratings Summary
APDN Quant Ranking